The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
By Tom Wilbur | July 22, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
By Tom Wilbur | July 2, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
By Tom Wilbur | June 5, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new treatments and cures for patients. Strong IP protections are...
Read More
IP Explained: Intellectual property system working to combat COVID-19
By Megan Van Etten | May 28, 2020
Biopharmaceutical companies are working around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among...
Read More
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
By Tom Wilbur | May 4, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP...
Read More
IP Explained: Four key takeaways from new Bayh-Dole white paper
By Tom Wilbur | February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...
Read More
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
By Tom Wilbur | November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...
Read More
IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act
By Tom Wilbur | October 9, 2019
In our last IP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical...
Read More
IP Explained: Four things to know about the Bayh-Dole Act
By Tom Wilbur | September 13, 2019
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...
Read More
IP Explained: Three forms of IP protections for medicines
By Tom Wilbur | August 27, 2019
Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
